EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report

Marco Donatello Delcuratolo, Maria Grazia Rodriquenz, Franco Morelli, Tiziana Pia Latiano, Lucia Anna Muscarella, Simona Caporilli, Lorenza Pasqualini, Elisabetta De Santis, Vincenzo Giambra, Antonio Rinaldi, Grazia Ciavarella, Matteo Floris und 10 weitere

Frontiers in Pharmacology · 04.08.2026 · 17

DOI: 10.3389/fphar.2026.1866621 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.08.2026. Verfasst von Marco Donatello Delcuratolo und 21 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fluoropyrimidines are widely used in the treatment of multiple neoplasms, but their use is limited by the risk of severe toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. Current clinical guidelines recommend DPYD genotyping as pre-treatment screening for a limited number of common variants; however, this approach fails to identify all patients at risk. Case Description We describe the case of a man with resected gastric adenocarcinoma, wild type for the DPYD recommended variants, who developed early-onset, life-threatening toxicity shortly after few days of adjuvant capecitabine-based chemotherapy at full dose. The clinical course was characterized by grade 4 gastrointestinal toxicity complicated by septic shock, which required prolonged hospitalization and led to the definitive discontinuation of chemotherapy. Extensive Next-Generation Sequencing (NGS) revealed a heterozygous deletion spanning from exons 5 to 20 (for a total of about 500 Kb) of the DPYD gene. The presence of this deletion was validated using Single Nucleotide Polymorphism (SNP) Array. Functional analysis, based on assessment of DPD activity in peripheral blood mononuclear cells (PBMCs) and plasma concentrations of uracil and dihydrouracil, confirmed the impaired DPD function.

Conclusion

This case highlights the limitations of routine DPYD genotyping strategies and emphasizes the clinical relevance of rare structural variants as an underestimated cause of severe fluoropyrimidine-related toxicity. The use of comprehensive NGS approach in pharmacogenetic diagnostics should be considered as a step forward in the identification of patients at risk of fluoropyrimidines-related toxicity particularly in the context of adjuvant therapy, where it is essential to strike a balance between therapeutic benefits and unacceptable toxicity.

Schlagwörter

Stichwörter der Autor:innen

DPD activityDPYD genecase reportfluoropyrimidine toxicitynext-generation sequencing

Autor:innen und Institutionen

  • Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
  • Lung Cancer Research Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
  • Life Sciences and Diagnostic Group, Agilent Technologies Italia S.p.A. Cernusco sul Naviglio, Milan, Italy.
  • Hematopathology Unit, Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapeutics (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
  • Medicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
  • Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Zitieren

APA

Delcuratolo, M. D., Rodriquenz, M. G., Morelli, F., Latiano, T. P., Muscarella, L. A., Caporilli, S., Pasqualini, L., De Santis, E., Giambra, V., Rinaldi, A., Ciavarella, G., Floris, M., Murru, R., Mascia, A., De Mattia, E., Canil, G., Fania, G., Pop, A., Carella, M., …, & Miscio, G. (2026). Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1866621

Vancouver

Delcuratolo MD, Rodriquenz MG, Morelli F, Latiano TP, Muscarella LA, Caporilli S, et al. Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1866621

BibTeX
@article{Delcuratolo2026,
  author = {Delcuratolo, Marco Donatello and Rodriquenz, Maria Grazia and Morelli, Franco and Latiano, Tiziana Pia and Muscarella, Lucia Anna and Caporilli, Simona and Pasqualini, Lorenza and De Santis, Elisabetta and Giambra, Vincenzo and Rinaldi, Antonio and Ciavarella, Grazia and Floris, Matteo and Murru, Roberta and Mascia, Alessia and De Mattia, Elena and Canil, Giovanni and Fania, Giuseppe and Pop, Ana and Carella, Massimo and van Kuilenburg, André and Cecchin, Erika and Miscio, Giuseppe},
  title = {Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1866621}
}
Kostenlos starten →